Endocannabinoid Dysregulation Disorders
Deviation from physiologically defined endocannabinoid concentrations may represent a measurable form of system dysregulation. When such deviations correlate with clinical phenotypes, they may be characterized within a biomarker-based diagnostic framework. AMCANN Research investigates endocannabinoid dysregulation as a quantifiable condition through population-based reference modeling and comparative analysis.
The Endocannabinoid System as a Measurable Signaling Network
The endocannabinoid system is a lipid signaling network composed of endogenously produced ligands, metabolic enzymes, and receptor-mediated pathways that regulate multiple physiological processes, including immune function, metabolic activity, and neurophysiological signaling. Despite its regulatory scope, the system is not currently represented within standard clinical laboratory panels. This absence reflects historical limitations in analytical methodology rather than a lack of physiological relevance. Quantitative assessment of endocannabinoid concentrations in human plasma requires high-sensitivity analytical techniques capable of detecting low-abundance lipid mediators within complex biological matrices.
AMCANN Research employs liquid chromatography–tandem mass spectrometry (LC–MS/MS) to measure endogenous cannabinoid ligands with sufficient sensitivity, specificity, and reproducibility for population-level analysis. These measurements support the development of reference intervals and enable the identification of statistically significant deviations associated with dysregulated signaling states.
